Is MediciNova Stock a Good Investment?
MediciNova Investment Advice | MNOV |
- Examine MediciNova's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MediciNova's leadership team and their track record. Good management can help MediciNova navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact MediciNova's business and its evolving consumer preferences.
- Compare MediciNova's performance and market position to its competitors. Analyze how MediciNova is positioned in terms of product offerings, innovation, and market share.
- Check if MediciNova pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MediciNova's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MediciNova stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MediciNova is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine MediciNova Stock
Researching MediciNova's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.23. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MediciNova recorded a loss per share of 0.17. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 31st of October 2006.
To determine if MediciNova is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MediciNova's research are outlined below:
| MediciNova generated a negative expected return over the last 90 days | |
| MediciNova may become a speculative penny stock | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (8.57 M) with profit before overhead, payroll, taxes, and interest of 4.04 M. | |
| MediciNova currently holds about 65.23 M in cash with (7.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| MediciNova has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: MediciNova investors are sitting on a loss of 89 percent if they invested five years ago |
MediciNova uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MediciNova. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MediciNova's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact MediciNova's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises MediciNova's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-09 | 2023-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2022-08-11 | 2022-06-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2019-04-25 | 2019-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2017-07-26 | 2017-06-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2016-10-25 | 2016-09-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2015-07-30 | 2015-06-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2015-03-13 | 2014-12-31 | -0.09 | -0.1 | -0.01 | 11 | ||
2022-11-10 | 2022-09-30 | -0.09 | -0.07 | 0.02 | 22 |
Know MediciNova's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MediciNova is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MediciNova backward and forwards among themselves. MediciNova's institutional investor refers to the entity that pools money to purchase MediciNova's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2023-12-31 | 133.4 K | Bank Of New York Mellon Corp | 2023-12-31 | 119.9 K | Barclays Plc | 2023-12-31 | 91.3 K | Schonfeld Strategic Advisors Llc | 2023-09-30 | 42.2 K | Millennium Management Llc | 2023-12-31 | 36.4 K | Goldman Sachs Group Inc | 2023-12-31 | 21.9 K | Susquehanna International Group, Llp | 2023-12-31 | 21.7 K | T. Rowe Price Associates, Inc. | 2023-12-31 | 20.7 K | Bank Julius Baer & Co. Ltd, Zurich | 2023-12-31 | 19 K | Essex Woodlands Health Ventures | 2023-12-31 | 1.1 M | Blackrock Inc | 2023-12-31 | 699.6 K |
MediciNova's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.27 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MediciNova's market, we take the total number of its shares issued and multiply it by MediciNova's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
MediciNova's profitablity analysis
MediciNova's profitability indicators refer to fundamental financial ratios that showcase MediciNova's ability to generate income relative to its revenue or operating costs. If, let's say, MediciNova is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, MediciNova's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of MediciNova's profitability requires more research than a typical breakdown of MediciNova's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.14) | (0.14) |
Determining MediciNova's profitability involves analyzing its financial statements and using various financial metrics to determine if MediciNova is a good buy. For example, gross profit margin measures MediciNova's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MediciNova's profitability and make more informed investment decisions.
The data published in MediciNova's official financial statements usually reflect MediciNova's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of MediciNova. For example, before you start analyzing numbers published by MediciNova accountants, it's critical to develop an understanding of what MediciNova's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of MediciNova's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MediciNova's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in MediciNova's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MediciNova. Please utilize our Beneish M Score to check the likelihood of MediciNova's management manipulating its earnings.
Evaluate MediciNova's management efficiency
MediciNova has return on total asset (ROA) of (0.0881) % which means that it has lost $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1293) %, meaning that it created substantial loss on money invested by shareholders. MediciNova's management efficiency ratios could be used to measure how well MediciNova manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, MediciNova's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 4.8 M in 2024, whereas Other Assets are likely to drop slightly above 101.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.27 | 1.21 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 0.98 | 0.93 | |
| Enterprise Value Over EBITDA | (2.31) | (2.42) | |
| Price Book Value Ratio | 1.18 | 1.63 | |
| Enterprise Value Multiple | (2.31) | (2.42) | |
| Price Fair Value | 1.18 | 1.63 | |
| Enterprise Value | 74 M | 82.8 M |
The analysis of MediciNova's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze MediciNova's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of MediciNova Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.687 |
Basic technical analysis of MediciNova Stock
As of the 2nd of May, MediciNova secures the Mean Deviation of 2.06, standard deviation of 2.62, and Risk Adjusted Performance of (0.03). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MediciNova, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down and interpolate data for thirteen technical drivers for MediciNova, which can be compared to its peers in the industry. Please verify MediciNova mean deviation and maximum drawdown to decide if MediciNova is priced some-what accurately, providing market reflects its recent price of 1.32 per share. Given that MediciNova is a hitting penny stock territory we strongly suggest to closely look at its jensen alpha.MediciNova's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MediciNova insiders, such as employees or executives, is commonly permitted as long as it does not rely on MediciNova's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MediciNova insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Masatsune Okajima over two months ago Exercise of in-the-money or at-the-money derivative position by Masatsune Okajima of 8400 shares of MediciNova | ||
Geoffrey OBrien over three months ago Acquisition by Geoffrey OBrien of 84000 shares of MediciNova subject to Rule 16b-3 |
Understand MediciNova's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MediciNova's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.87) | |||
| Mean Deviation | 2.06 | |||
| Coefficient Of Variation | (1,594) | |||
| Standard Deviation | 2.62 | |||
| Variance | 6.85 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.38) | |||
| Treynor Ratio | (0.88) | |||
| Maximum Drawdown | 14.01 | |||
| Value At Risk | (3.95) | |||
| Potential Upside | 4.55 | |||
| Skewness | 0.5159 | |||
| Kurtosis | 0.6287 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.87) | |||
| Mean Deviation | 2.06 | |||
| Coefficient Of Variation | (1,594) | |||
| Standard Deviation | 2.62 | |||
| Variance | 6.85 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.38) | |||
| Treynor Ratio | (0.88) | |||
| Maximum Drawdown | 14.01 | |||
| Value At Risk | (3.95) | |||
| Potential Upside | 4.55 | |||
| Skewness | 0.5159 | |||
| Kurtosis | 0.6287 |
Consider MediciNova's intraday indicators
MediciNova intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MediciNova stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MediciNova time-series forecasting models is one of many MediciNova's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MediciNova's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
MediciNova Stock media impact
Far too much social signal, news, headlines, and media speculation about MediciNova that are available to investors today. That information is available publicly through MediciNova media outlets and privately through word of mouth or via MediciNova internal channels. However, regardless of the origin, that massive amount of MediciNova data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MediciNova news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MediciNova relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MediciNova's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MediciNova alpha.
MediciNova Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards MediciNova can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in MediciNova without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
MediciNova Corporate Management
Elected by the shareholders, the MediciNova's board of directors comprises two types of representatives: MediciNova inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MediciNova. The board's role is to monitor MediciNova's management team and ensure that shareholders' interests are well served. MediciNova's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MediciNova's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Masatsune Okajima | Head of Japanese Office and VP | Profile | |
| Jason CPA | CFO Officer | Profile | |
| Kazuko Matsuda | Chief Medical Officer | Profile | |
| Dr MBA | Chief Officer | Profile |
How to buy MediciNova Stock?
To provide specific investment advice or recommendations on MediciNova stock, we recommend investors consider the following general factors when evaluating MediciNova. This will help you to make an informed decision on whether to include MediciNova in one of your diversified portfolios:- Examine MediciNova's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MediciNova's leadership team and their track record. Good management can help MediciNova navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact MediciNova's business and its evolving consumer preferences.
- Compare MediciNova's performance and market position to its competitors. Analyze how MediciNova is positioned in terms of product offerings, innovation, and market share.
- Check if MediciNova pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MediciNova's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MediciNova stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MediciNova is a good investment.
Already Invested in MediciNova?
The danger of trading MediciNova is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of MediciNova is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than MediciNova. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile MediciNova is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether MediciNova is a strong investment it is important to analyze MediciNova's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MediciNova's future performance. For an informed investment choice regarding MediciNova Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MediciNova. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for MediciNova Stock analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is MediciNova's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MediciNova. If investors know MediciNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MediciNova listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.17) | Revenue Per Share 0.02 | Return On Assets (0.09) | Return On Equity (0.13) |
The market value of MediciNova is measured differently than its book value, which is the value of MediciNova that is recorded on the company's balance sheet. Investors also form their own opinion of MediciNova's value that differs from its market value or its book value, called intrinsic value, which is MediciNova's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MediciNova's market value can be influenced by many factors that don't directly affect MediciNova's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between MediciNova's value and its price, as these two are different measures arrived at by various means. Investors typically determine if MediciNova is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MediciNova's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.